Monitoring the Quality of Antimalarial Medicines Circulating in Kenya

Good quality medicine is a pre requisite to prompt and effective treatment, the main objective of case management according to the current national malaria strategy. This first round of the monitoring of the quality of antimalarials was carried out in April and May 2010 in five sentinel sites representing areas with the highest malaria burden.

In total, 536 antimalarial samples were collected from the five sentinel sites according to the endemicity of Malaria. The samples included artemisinin-based combination therapy (ACT) and sulfadoxine-Pyrimethamine (SPs) among other antimalarials. The samples were collected from the public sector, the private sector and the informal sector.

Basic testing, using the Global Pharma Health Fund (GPHF) Minilab kit, was performed on most collected samples at the sentinel sites. This was followed by confirmatory analysis of 10% of the samples that passed minilab analysis, all doubtful samples and all failed samples at the National Quality Control Laboratory (NQCL) using the Minilab.

The samples which failed were then subjected to full scale quality control laboratory testing using compendial methods at the same laboratory.

Of the 536 samples collected, all were assessed for registration status with PPB, 519 were analyzed using minilabs at level 1, 80 at level 2 and 44 using compendial methods in NQCL. The study findings indicate that 94% of the samples collected were registered, 92% conformed at level one, 76% conformed at level two and 84% conformed to compendial methods (level three).


Malaria PMS Report – Round 1

Malaria PMS Report – Round 2

Malaria PMS Report – Round 3

Malaria PMS Report – Round 4

PPB News